Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma

INTRODUCTION: Bevacizumab has demonstrated activity in glioblastoma (GBM), but the true benefits and optimal dose‐schedule are debated. A lower dose‐schedule than standard‐dose bevacizumab (10 mg/kg 2‐weekly) might offer similar benefits with lower costs. At our Institution, patients are randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gleeson, Jack Patrick, Keane, Fergus, Keegan, Niamh M., Mammadov, Emin, Harrold, Emily, Alhusaini, Abdullah, Harte, Jeffrey, Eakin‐Love, Austin, O'Halloran, Philip J., MacNally, Stephen, Hennessy, Bryan T., Breathnach, Oscar S., Grogan, Liam, Morris, Patrick G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970030/
https://www.ncbi.nlm.nih.gov/pubmed/31756059
http://dx.doi.org/10.1002/cam4.2616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970030/
https://www.ncbi.nlm.nih.gov/pubmed/31756059
http://dx.doi.org/10.1002/cam4.2616

Ejemplares similares